Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG)
详细信息 查看全文
- 作者：N. Kentepozidis ; P. Economopoulou…
- 关键词：Platinum ; based chemotherapy ; Advanced NSCLC ; Irinotecan/cisplatin ; Pemetrexed/cisplatin ; Second ; line treatment
- 刊名：Clinical and Translational Oncology
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：19
- 期：3
- 页码：317-325
- 全文大小：
- 刊物主题：Oncology;
- 出版者：Springer International Publishing
- ISSN：1699-3055
- 卷排序：19
文摘
BackgroundPlatinum-based chemotherapy is the standard front-line treatment for patients with advanced non-small cell lung cancer (NSCLC). However, non-platinum combinations of third-generation chemotherapeutic agents are considered an alternative therapeutic option for patients who cannot tolerate the toxic effects of platinum compounds. In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-naïve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine.